Tower Research Capital LLC TRC Has $31,000 Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

Tower Research Capital LLC TRC reduced its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 56.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,640 shares of the company’s stock after selling 6,114 shares during the period. Tower Research Capital LLC TRC’s holdings in Nkarta were worth $31,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Innovis Asset Management LLC acquired a new stake in shares of Nkarta during the 3rd quarter valued at $193,000. Bleakley Financial Group LLC purchased a new position in Nkarta in the fourth quarter valued at about $70,000. Bailard Inc. acquired a new position in Nkarta in the 4th quarter worth about $106,000. Acadian Asset Management LLC purchased a new stake in shares of Nkarta during the 3rd quarter worth about $89,000. Finally, Simplicity Solutions LLC acquired a new stake in shares of Nkarta during the 4th quarter valued at about $70,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Nkarta

In other news, insider James Trager sold 4,143 shares of Nkarta stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $12.00, for a total transaction of $49,716.00. Following the sale, the insider now owns 149,415 shares of the company’s stock, valued at approximately $1,792,980. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider James Trager sold 4,143 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $12.00, for a total value of $49,716.00. Following the completion of the transaction, the insider now owns 149,415 shares in the company, valued at approximately $1,792,980. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Simeon George bought 2,000,000 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $20,000,000.00. Following the completion of the transaction, the director now owns 1,548,341 shares in the company, valued at approximately $15,483,410. The disclosure for this purchase can be found here. Corporate insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

NKTX has been the topic of several recent research reports. HC Wainwright cut their price objective on shares of Nkarta from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Nkarta in a research note on Wednesday, April 10th. Raymond James reissued an “outperform” rating and set a $16.00 target price (up from $13.00) on shares of Nkarta in a research report on Friday, March 22nd. Canaccord Genuity Group raised their target price on Nkarta from $15.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Finally, Mizuho decreased their price target on Nkarta from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, March 22nd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $17.83.

Nkarta Price Performance

NKTX stock traded down $0.13 on Friday, reaching $7.40. 820,344 shares of the company were exchanged, compared to its average volume of 936,655. The firm has a market capitalization of $365.68 million, a PE ratio of -3.08 and a beta of 0.88. Nkarta, Inc. has a 12 month low of $1.28 and a 12 month high of $16.24. The stock’s fifty day moving average price is $10.15 and its 200 day moving average price is $7.15.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.05. As a group, research analysts expect that Nkarta, Inc. will post -2.36 EPS for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.